Nothing Special   »   [go: up one dir, main page]

SG11202010154UA - Method for enhancing the suppressive properties of treg cells - Google Patents

Method for enhancing the suppressive properties of treg cells

Info

Publication number
SG11202010154UA
SG11202010154UA SG11202010154UA SG11202010154UA SG11202010154UA SG 11202010154U A SG11202010154U A SG 11202010154UA SG 11202010154U A SG11202010154U A SG 11202010154UA SG 11202010154U A SG11202010154U A SG 11202010154UA SG 11202010154U A SG11202010154U A SG 11202010154UA
Authority
SG
Singapore
Prior art keywords
enhancing
treg cells
suppressive properties
suppressive
properties
Prior art date
Application number
SG11202010154UA
Inventor
Hans Stauss
Jenny L Mcgovern
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806330.5A external-priority patent/GB201806330D0/en
Priority claimed from GBGB1806331.3A external-priority patent/GB201806331D0/en
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of SG11202010154UA publication Critical patent/SG11202010154UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
SG11202010154UA 2018-04-18 2019-04-17 Method for enhancing the suppressive properties of treg cells SG11202010154UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1806330.5A GB201806330D0 (en) 2018-04-18 2018-04-18 Engineered regulatory T cell
GBGB1806331.3A GB201806331D0 (en) 2018-04-18 2018-04-18 Method
PCT/GB2019/051098 WO2019202323A1 (en) 2018-04-18 2019-04-17 Method for enhancing the suppressive properties of treg cells

Publications (1)

Publication Number Publication Date
SG11202010154UA true SG11202010154UA (en) 2020-11-27

Family

ID=66286535

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010154UA SG11202010154UA (en) 2018-04-18 2019-04-17 Method for enhancing the suppressive properties of treg cells

Country Status (11)

Country Link
US (2) US12077774B2 (en)
EP (2) EP3781673A1 (en)
JP (3) JP7436383B2 (en)
KR (1) KR20210003810A (en)
CN (2) CN112004924A (en)
AU (2) AU2019254824A1 (en)
CA (2) CA3105303A1 (en)
GB (3) GB2611498B (en)
IL (1) IL278016B1 (en)
SG (1) SG11202010154UA (en)
WO (2) WO2019202322A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202010154UA (en) 2018-04-18 2020-11-27 Ucl Business Ltd Method for enhancing the suppressive properties of treg cells
GB201915359D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
AU2021373326A1 (en) * 2020-11-09 2023-06-22 Quell Therapeutics Ltd Method for cryopreserving engineered tregs
WO2022103789A1 (en) 2020-11-10 2022-05-19 Kyverna Therapeutics, Inc. A method for treating disease using foxp3+cd4+ t cells
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
WO2023048275A1 (en) * 2021-09-27 2023-03-30 国立大学法人京都大学 Method for producing t cell
WO2023111594A1 (en) 2021-12-17 2023-06-22 Quell Therapeutics Limited Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
US20230210900A1 (en) * 2022-01-04 2023-07-06 Kyverna Therapeutics, Inc. Methods for treating autoimmune diseases
WO2023180690A1 (en) 2022-03-22 2023-09-28 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
WO2023214182A1 (en) * 2022-05-05 2023-11-09 Quell Therapeutics Limited Method for maintaining suppressive activity of regulatory t cells
CN116284447A (en) * 2023-02-20 2023-06-23 苏州大学 PD1 chimeric antigen receptor-modified regulatory T cell targeted as well as preparation method and application thereof
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP3095175B2 (en) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
DE69943129D1 (en) 1998-08-11 2011-02-24 Darwin Discovery Ltd IDENTIFICATION OF THE GENE THAT LEADS TO THE TIMELY PHENOTYPE OF MOUSE, AS WELL AS ITS HUMAN ORTHOLOGIST
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
DE60228477D1 (en) 2001-05-08 2008-10-02 Darwin Molecular Corp PROCESS FOR REGULATING THE IMMUNE FUNCTION IN PRIMATES USING THE FOXP3 PROTEIN
FR2825261B1 (en) 2001-06-01 2003-09-12 Maco Pharma Sa PLACENTAL BLOOD COLLECTION LINE COMPRISING A RINSING POCKET
AU2004252465A1 (en) 2003-06-13 2005-01-06 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
CA2609731A1 (en) 2005-05-24 2006-11-30 Avestha Gengraine Technologies Pvt Ltd. A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma
US20100135974A1 (en) 2007-01-31 2010-06-03 Yeda Research And Development Co. Ltd. Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
JP5626164B2 (en) 2011-07-26 2014-11-19 日本精工株式会社 Steering column support device
US20150073043A1 (en) * 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
RU2523058C2 (en) 2012-06-29 2014-07-20 Общество с ограниченной ответственностью "Регенекс" Method of therapy of remittent multiple sclerosis
US9693977B2 (en) 2013-03-15 2017-07-04 President And Fellows Of Harvard College Method of increasing the quantity of colonic T regulatory cells via G-coupled protein receptor 43
WO2014183056A1 (en) * 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
GB201322430D0 (en) * 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
AU2015362753A1 (en) 2014-12-15 2017-04-27 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
EP3259284B1 (en) * 2015-02-16 2020-04-01 The Trustees of the University of Pennsylvania A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
WO2017058752A1 (en) 2015-09-28 2017-04-06 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
CA3012009A1 (en) 2015-10-09 2017-04-13 Abt Holding Company Methods for enhancing proliferation of t regulatory cells
US10604586B2 (en) 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
US11547748B2 (en) 2016-06-30 2023-01-10 Hoffmann-La Roche Inc. Adoptive t-cell therapy
EP3714944A1 (en) 2019-03-29 2020-09-30 Medizinische Hochschule Hannover Car for use in the treatment of hvg disease
CN111107866A (en) 2017-06-12 2020-05-05 黑曜石疗法公司 PDE5compositions and methods for immunotherapy
WO2018236909A1 (en) 2017-06-20 2018-12-27 La Jolla Institute For Allergy And Immunology Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis
WO2019079034A1 (en) * 2017-10-17 2019-04-25 The General Hospital Corporation Methods and compositions relating to engineered regulatory t cells
SG11202010154UA (en) 2018-04-18 2020-11-27 Ucl Business Ltd Method for enhancing the suppressive properties of treg cells
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
WO2020237045A1 (en) 2019-05-21 2020-11-26 Sangamo Therapeutics, Inc. Controlled transgene expression in regulatory t cells
GB201915384D0 (en) 2019-10-23 2019-12-04 Ucl Business Ltd Vector
GB201915359D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy

Also Published As

Publication number Publication date
US12077774B2 (en) 2024-09-03
CA3105303A1 (en) 2019-10-24
CA3098128A1 (en) 2019-10-24
IL278016A (en) 2020-11-30
US20210145884A1 (en) 2021-05-20
GB2587988A (en) 2021-04-14
KR20210003810A (en) 2021-01-12
WO2019202323A1 (en) 2019-10-24
GB202300872D0 (en) 2023-03-08
CN112334571B (en) 2024-06-25
GB2611707A (en) 2023-04-12
EP3781672A1 (en) 2021-02-24
IL278016B1 (en) 2024-11-01
GB202300916D0 (en) 2023-03-08
JP7391038B2 (en) 2023-12-04
CN112004924A (en) 2020-11-27
GB2587988B (en) 2023-05-31
WO2019202322A1 (en) 2019-10-24
JP2021520831A (en) 2021-08-26
US20210079425A1 (en) 2021-03-18
AU2019254824A1 (en) 2020-11-26
JP7436383B2 (en) 2024-02-21
EP3781673A1 (en) 2021-02-24
GB2611498B (en) 2023-07-19
CN112334571A (en) 2021-02-05
GB2611498A (en) 2023-04-05
GB202018103D0 (en) 2020-12-30
JP2024026127A (en) 2024-02-28
JP2021520834A (en) 2021-08-26
AU2019256783A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
IL278016A (en) Method for enhancing the suppressive properties of treg cells
EP3602672A4 (en) System and method for treating the surface of solid electrolytes
IL276131A (en) Methods of use for car t cells
EP3432320A4 (en) Solid electrolyte and method for producing solid electrolyte
EP3408641A4 (en) Methods and apparatus for multi-view characterization
IL266454B (en) Implant and method for forming the implant
EP3766984A4 (en) Determination method`
IL283948A (en) Methods for the treatment of depression
EP3242640A4 (en) Hybrid device for surgical aortic repair and method of using the same
EP3585511A4 (en) Metal-molybdate and method for making the same
EP3632905A4 (en) Method for preparing n-acyl ortho-aminobenzamide
ZA202101685B (en) Method and system for quantum-resistant hashing scheme
IL272559B (en) Method for the preparation of 4-(heptafluoro-2-propyl) anilines
PL3611119T3 (en) Feed charging bridge and method for operating the same
EP3734277A4 (en) Method for assessing medicine
ZA201807469B (en) Method for identifying snoring
EP3602036A4 (en) Method for the determination of film forming amines
IL275612A (en) Method for preparing bap or ba cells
EP3380844A4 (en) Method for verifying the primary structure of protein
EP3729851A4 (en) Method for detecting the possible taking of screenshots
PL3609839T3 (en) Method for the management of phosphogypsum
EP3547176A4 (en) Apparatus and method for determining circulatory disease potential
EP3114491A4 (en) Method and device for testing the connections of batteries
EP3859006A4 (en) Determination method
EP3543688A4 (en) Inspection method